Squamous Cell Carcinoma of Skin near Brandon, FL

Care Philosophy: Dr Eroglu is a medical oncologist in the Department of Cutaneous Oncology at Moffitt Cancer Center and an assistant professor in the Department of Oncologic Sciences at the University of South Florida Morsani College of Medicine. Her clinical focus is on treating patients with advanced melanoma and other skin cancers, including basal cell carcinoma and Merkel cell carcinoma, and participating in clinical trials.Dr Eroglu's research interests are translational and clinical research in targeted therapies and combination immunotherapeutics for melanoma and other skin cancers, along with development of personalized treatment strategies and biomarkers for patients with melanoma.

Care Philosophy: Dr Guilherme Rabinowits is a Senior Member in the Department of Head and Neck-Endocrine Oncology. Dr Rabinowits received his MD degree from Fundacao Tecnico-Educacional Souza Marques, Rio de Janeiro, Brazil. He completed an Internal Medicine residency at Lahey Clinic and Medical Center, Burlington, Massachusetts, followed by a Hematology/Medical Oncology Fellowship at the University of Louisville, Kentucky, where he also served as Chief Fellow. He then joined Dana-Farber Cancer Institute/Harvard Medical School, Boston, Massachusetts, as a Head and Neck Medical Oncologist until his move to Miami. Dr Rabinowits joins us from the Miami Cancer Institute, Department of Hematology/Medical Oncology.

Care Philosophy: Ahmad Tarhini, MD, PhD is an internationally recognized physician and leading researcher in Melanoma, Skin Cancers and Immuno-Oncology. Dr Tarhini is a Tenured Senior Member in the Moffitt Cancer Center and Research Institute Departments of Cutaneous Oncology and Immunology. Dr Tarhini also serves as the Director of Cutaneous Clinical and Translational Research and leader of the Neoadjuvant and Adjuvant Translational Science Program. He is Professor of Oncologic Sciences at the University of South Florida Morsani College of Medicine. Dr Tarhini also serves as Chair, Scientific Committee, Oncology Research Information Exchange Network (ORIEN) and Chair, ORIEN ImmunoOncology Research Subcommittee.

Care Philosophy: Over the past fifteen years, Dr Sokol's clinical and laboratory work has been focused on T-cell lymphomas and leukemias and rare lymphoproliferative and histiocytic disorders including Castleman disease, Langerhans Cell Histiocytosis, Hemophagocytic LymphoHistiocytosis, Rosai-Dorfman Disease, etc. He has participated in numerous clinical trials for T cell malignancies including pivotal studies with romidepsin and mogamulizumab. He also led clinical research in T-cell and NK-cell large granular lymphocytic leukemia (LGL). Dr Sokol has been the Co-Director of the Cutaneous Lymphoma Multidisciplinary Clinic for over 15 years. This clinic is the largest referral center for patients with cutaneous T cell lymphoma (CTCL) in the southeastern U.S.

Care Philosophy: Dr Chung's laboratory was among the first to recognize the importance of human papillomavirus (HPV) in the etiology of certain HNC as seen in one of the four subtypes in our molecular characterization study. Specifically the research showed that the most significantly deregulated genes in the HPV-positive tumors are cell cycle regulators. These data provided evidence that HPV-positive tumors may be more sensitive to chemotherapy and molecular inhibitors that specifically target cell cycle. In addition, her research findings contributed to establish the prognostic implication of the HPV status. Patients with HPV-positive HNC have a better prognosis compared to patients with HPV-negative HNC.